Roche's New Gene-sequencing Tool to Drive Diagnostics Growth

Dow Jones06-29

1114 GMT - Roche Holding's new gene-sequencing platform will be a growth driver for the Swiss group's diagnostics division in coming years, which in turn should help the hit from drug-patent losses in its pharma business next decade, Bernstein analysts say. The gene-sequencing platform, alongside new mass-spectrometry and glucose-monitoring products- mean Roche's diagnostics business is at its most important inflection point in 25 years, the analysts say in a research note. The three new technologies should significantly increase Roche's presence in the profitable U.S. market, and help it deliver annual sales growth of 9% over the 2025-35 period, according to Bernstein. Shares rise 0.1%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

June 29, 2026 07:14 ET (11:14 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2647331376?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-29 19:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2647331376","market":"sg","top_or_hot":-1,"title":"Roche's New Gene-sequencing Tool to Drive Diagnostics Growth","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1114 GMT - Roche Holding's new gene-sequencing platform will be a growth driver for the Swiss group's diagnostics division in coming years, which in turn should help the hit from drug-patent losses in its pharma business next decade, Bernstein analysts say. The gene-sequencing platform, alongside new mass-spectrometry and glucose-monitoring products- mean Roche's diagnostics business is at its most important inflection point in 25 years, the analysts say in a research note. The three new technologies should significantly increase Roche's presence in the profitable U.S. market, and help it deliver annual sales growth of 9% over the 2025-35 period, according to Bernstein. Shares rise 0.1%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 29, 2026 07:14 ET (11:14 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche's New Gene-sequencing Tool to Drive Diagnostics Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche's New Gene-sequencing Tool to Drive Diagnostics Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-29 19:14</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1114 GMT - Roche Holding's new gene-sequencing platform will be a growth driver for the Swiss group's diagnostics division in coming years, which in turn should help the hit from drug-patent losses in its pharma business next decade, Bernstein analysts say. The gene-sequencing platform, alongside new mass-spectrometry and glucose-monitoring products- mean Roche's diagnostics business is at its most important inflection point in 25 years, the analysts say in a research note. The three new technologies should significantly increase Roche's presence in the profitable U.S. market, and help it deliver annual sales growth of 9% over the 2025-35 period, according to Bernstein. Shares rise 0.1%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 29, 2026 07:14 ET (11:14 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03165","symbol_name":"华夏欧优股对冲","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2647331376","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2647331376","pubTimestamp":1782731640,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1114 GMT - Roche Holding's new gene-sequencing platform will be a growth driver for the Swiss group's diagnostics division in coming years, which in turn should help the hit from drug-patent losses in its pharma business next decade, Bernstein analysts say. The gene-sequencing platform, alongside new mass-spectrometry and glucose-monitoring products- mean Roche's diagnostics business is at its most important inflection point in 25 years, the analysts say in a research note. The three new technologies should significantly increase Roche's presence in the profitable U.S. market, and help it deliver annual sales growth of 9% over the 2025-35 period, according to Bernstein. Shares rise 0.1%.  Dow Jones NewswiresJune 29, 2026 07:14 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03165":"华夏欧优股对冲","RHHBY":"罗氏控股","BK4007":"制药"},"translate_title":"罗氏新基因测序工具推动诊断增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RHHBY":0.9,"03165":0.6},"content_text":"1114 GMT - Roche Holding's new gene-sequencing platform will be a growth driver for the Swiss group's diagnostics division in coming years, which in turn should help the hit from drug-patent losses in its pharma business next decade, Bernstein analysts say. The gene-sequencing platform, alongside new mass-spectrometry and glucose-monitoring products- mean Roche's diagnostics business is at its most important inflection point in 25 years, the analysts say in a research note. The three new technologies should significantly increase Roche's presence in the profitable U.S. market, and help it deliver annual sales growth of 9% over the 2025-35 period, according to Bernstein. Shares rise 0.1%. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 29, 2026 07:14 ET (11:14 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.0","shortVersion":"4.45.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2647331376","isCrawlerRequest":true}